Robert Allen III Sells 18,189 Shares of Invivyd (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Robert Allen III sold 18,189 shares of Invivyd stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $1.54, for a total value of $28,011.06. Following the completion of the sale, the insider directly owned 133,879 shares in the company, valued at approximately $206,173.66. This represents a 11.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Invivyd Stock Performance

NASDAQ IVVD traded up $0.10 during trading on Wednesday, hitting $1.65. The stock had a trading volume of 1,468,415 shares, compared to its average volume of 3,015,442. Invivyd, Inc. has a 12 month low of $0.46 and a 12 month high of $3.07. The company’s 50-day moving average price is $2.19 and its two-hundred day moving average price is $1.75. The company has a market capitalization of $384.65 million, a PE ratio of -3.51 and a beta of 0.60.

Analyst Ratings Changes

A number of brokerages have recently issued reports on IVVD. Zacks Research upgraded Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. HC Wainwright lifted their price objective on shares of Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Invivyd in a research report on Monday, December 29th. BTIG Research reissued a “buy” rating on shares of Invivyd in a report on Wednesday, January 21st. Finally, D. Boral Capital reaffirmed a “hold” rating on shares of Invivyd in a report on Tuesday, November 25th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $8.00.

Hedge Funds Weigh In On Invivyd

Large investors have recently made changes to their positions in the company. Courier Capital LLC acquired a new stake in Invivyd during the 4th quarter worth approximately $25,000. Bronte Capital Management Pty Ltd. acquired a new position in Invivyd in the 4th quarter valued at $27,000. DRW Securities LLC bought a new position in Invivyd during the 4th quarter worth $27,000. ProShare Advisors LLC acquired a new stake in shares of Invivyd during the fourth quarter worth $30,000. Finally, State of Wyoming bought a new stake in shares of Invivyd in the fourth quarter valued at about $30,000. Institutional investors own 70.36% of the company’s stock.

Key Invivyd News

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Multiple Form 4 filings disclose open‑market sales (no new corporate/clinical announcements). The disclosures are routine SEC insider-sale filings rather than earnings or clinical-data releases. Representative SEC Filing
• Neutral Sentiment: Aggregate size and liquidity context — filings show insiders sold a total of over ~220,000 shares across Feb. 17–18 (multiple executives, see items below). Today’s volume (≈1.47M) is below the stock’s 3M average, which can amplify price moves on relatively modest buying or selling flows.
• Negative Sentiment: Jill Andersen — sold 32,771 shares on 2/17 at ~$1.54 and 34,939 shares on 2/18 at ~$1.58; filings show a double‑digit percentage reduction in her holdings. SEC Filing – Jill Andersen
• Negative Sentiment: Timothy Edward Lee — sold 19,663 shares on 2/17 at ~$1.54 and 20,964 on 2/18 at ~$1.58; each sale reduced his ownership by ~12–15%. SEC Filing – Timothy Lee
• Negative Sentiment: William E. Duke (CFO) — sold 19,663 shares on 2/17 at ~$1.54 and 20,964 on 2/18 at ~$1.58; filings show ~13–16% reductions in his holdings. SEC Filing – William Duke
• Negative Sentiment: Julie Green — sold 19,663 shares on 2/17 at ~$1.54 and 20,964 on 2/18 at ~$1.58; each sale trimmed her stake by ~13–16%. SEC Filing – Julie Green
• Negative Sentiment: Robert D. Allen III — sold 18,189 shares on 2/17 at ~$1.54 and 19,392 on 2/18 at ~$1.58; filings show ~12–14% reductions in his holdings. SEC Filing – Robert Allen

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.